MK-677 (Ibutamoren) vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
MK-677 (Ibutamoren)Fat Loss & Metabolic
AOD-9604- Summary
- MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- 24 hours
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- Oral
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 10–25 mg
- 300-600 mcg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Increases lean muscle mass
- Enhances bone density
- Improves sleep quality and REM sleep
- Accelerates recovery from training
- Increases appetite
- May improve skin elasticity and appearance
- Supports fat loss while maintaining muscle
- Oral administration — no injections required
- 24-hour half-life allows once-daily dosing
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Increased appetite (significant in some users)
- Water retention and puffiness
- Elevated blood glucose / insulin resistance (monitor in diabetics)
- Lethargy initially
- +2 more
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —